Equities research analysts predict that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will announce earnings per share (EPS) of $0.09 for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Pacira Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.18 and the lowest estimate coming in at $0.01. Pacira Pharmaceuticals reported earnings per share of $0.11 during the same quarter last year, which would suggest a negative year-over-year growth rate of 18.2%. The company is scheduled to report its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Pacira Pharmaceuticals will report full-year earnings of $0.53 per share for the current fiscal year, with EPS estimates ranging from $0.40 to $0.69. For the next year, analysts expect that the business will report earnings of $1.09 per share, with EPS estimates ranging from ($0.44) to $1.87. Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Thursday, August 2nd. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.37. The firm had revenue of $84.10 million for the quarter, compared to analyst estimates of $77.53 million. Pacira Pharmaceuticals had a negative return on equity of 0.39% and a negative net margin of 3.64%. The company’s quarterly revenue was up 18.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) earnings per share.

A number of research firms have recently commented on PCRX. Royal Bank of Canada set a $55.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, September 19th. ValuEngine lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 2nd. Canaccord Genuity set a $49.00 price target on Pacira Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, October 2nd. Stifel Nicolaus began coverage on Pacira Pharmaceuticals in a research report on Thursday, September 13th. They set a “sell” rating and a $41.00 price target on the stock. Finally, Bank of America raised their price target on Pacira Pharmaceuticals from $46.00 to $48.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 10th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $48.00.

NASDAQ PCRX opened at $47.01 on Friday. The stock has a market cap of $2.01 billion, a PE ratio of -81.05 and a beta of 1.86. The company has a current ratio of 8.58, a quick ratio of 7.79 and a debt-to-equity ratio of 0.98. Pacira Pharmaceuticals has a one year low of $26.95 and a one year high of $52.60.

In related news, Director Mark A. Kronenfeld purchased 1,000 shares of the firm’s stock in a transaction on Tuesday, August 28th. The stock was purchased at an average cost of $44.61 per share, for a total transaction of $44,610.00. Following the completion of the purchase, the director now directly owns 8,577 shares in the company, valued at $382,619.97. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Lauren Bullaro Riker sold 1,667 shares of the firm’s stock in a transaction that occurred on Wednesday, August 22nd. The shares were sold at an average price of $44.48, for a total value of $74,148.16. Following the completion of the transaction, the vice president now owns 10,474 shares of the company’s stock, valued at $465,883.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,502 shares of company stock valued at $1,913,864. 5.90% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. State of Wisconsin Investment Board grew its stake in Pacira Pharmaceuticals by 3.0% in the second quarter. State of Wisconsin Investment Board now owns 40,600 shares of the company’s stock valued at $1,301,000 after purchasing an additional 1,200 shares in the last quarter. Rhumbline Advisers grew its stake in Pacira Pharmaceuticals by 3.5% in the second quarter. Rhumbline Advisers now owns 39,897 shares of the company’s stock valued at $1,279,000 after purchasing an additional 1,335 shares in the last quarter. Summit Trail Advisors LLC grew its stake in Pacira Pharmaceuticals by 12.9% in the first quarter. Summit Trail Advisors LLC now owns 15,103 shares of the company’s stock valued at $400,000 after purchasing an additional 1,728 shares in the last quarter. US Bancorp DE grew its stake in Pacira Pharmaceuticals by 40.7% in the second quarter. US Bancorp DE now owns 6,038 shares of the company’s stock valued at $194,000 after purchasing an additional 1,746 shares in the last quarter. Finally, Pendal Group Ltd grew its stake in Pacira Pharmaceuticals by 9.3% in the second quarter. Pendal Group Ltd now owns 23,326 shares of the company’s stock valued at $748,000 after purchasing an additional 1,975 shares in the last quarter.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Recommended Story: Risk Tolerance

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.